Select a community
HIV
Find out more about the PatientsLikeMe
HIV Community
Home > Community Treatment Reports > Pregabalin Treatment Report
What is Pregabalin?

Pregabalin is an analgesic and anti-convulsant drug that is used to manage pain associated with diabetic peripheral neuropathy, postherpetic (shingles) neuralgia, as an adjunctive treatment for partial-onset seizure disorder in adults and for the management of fibromyalgia.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
neuopathy pain 5 2
Other 4 0
Peripheral neuritis (neuropathy) 3 1
Aches and pains 1 0
Pain 1 0
Support another treatment 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
2 67%
Mild
0 0%
None
1 33%

Most commonly reported side effects

Daytime sleepiness
2 67%
Blurred Vision
1 33%
tiredness
1 33%
Brain fog
1 33%
Increased fatigue
1 33%
lack of concentration
1 33%
  • Mild
  • Moderate
  • Severe

Dosages

  150mg as needed daily 50 mg daily 75 mg daily 100 mg daily 150 mg daily 180 mg daily 300 mg daily 400 mg daily 450 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 6 Number of Patients: 6 1 Number of Patients: 1 5 Number of Patients: 5 1 Number of Patients: 1 2 Number of Patients: 2  

Duration See details about how long patients take this treatment ▼

Currently Taking Pregabalin

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
1
5
0
3

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
2 67%
Usually
1 33%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
2 67%
A little
0 0%
Not at all
1 33%

Cost

Paid out of pocket

$200+
0 0%
$100-199
1 33%
$50-99
0 0%
$25-49
0 0%
< $25
2 67%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.